

classified in class 530, subclass 370, for example.

Applicants respectfully traverse the restriction requirement, and provisionally elect Group I claims 1, 2, and 4-9 for further prosecution.

Applicants submit that the complete examination of the application would be handled most expeditiously by treating all of the pending claims as a single entity. As Section 803 of the MPEP directs, “[i]f the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it includes claims to distinct or independent inventions.” Applicants respectfully submit that the Examiner has not shown that a search and examination of the entire application would cause a serious burden. Rather, a serious burden would arise if the application were restricted.

Applicants submit that the restriction requirement is inappropriate. For example, Applicants contend that Group I and Group II should be examined simultaneously because they are related as nucleic acids and proteins encoded by such nucleic acids. Accordingly, examination of Group I and II together would pose no undue burden to the Examiner.


Furthermore, Applicants submit that restriction to a single nucleotide sequence is improper and Applicants believe no serious burden would result by the search and examination of at least ten nucleotide sequences. Applicants disagree that each nucleotide sequence in the application is necessarily a patentably distinct species, but provisionally elect the nucleic acids represented by SEQ ID NO: 22239 for further prosecution.

Based upon the foregoing, Applicants submit that the restriction requirement is improper and therefore should be withdrawn. To facilitate prosecution, however, Applicants have provisionally elected, with traverse, Group I claims 1, 2, and 4-9 and SEQ ID NO: 22239.

Should the Examiner have any questions regarding this application, the Examiner is encouraged to contact Applicants' undersigned representative at (314) 694-3602.

Respectfully submitted,

DATE: 7/22/04



Lawrence M. Lavin Jr.
(Registration NO. 30,768)

Patent Department E2NA
MONSANTO COMPANY
800 N. Lindbergh Blvd.
St. Louis, MO 63167
Telephone: (314) 694-3602
FAX: (314) 694-9009